ARCHIVE JUNE 2007

LONDON REGENERATIVE MEDICINE NETWORK

6.00 pm Thursday 7th June 2007


The June meeting of the London Regenerative Medicine Network is to be held in the evening of Thursday 7th June at the Guy’s Hospital Campus of King's College London at London Bridge - Lecture Theatre 2, New Hunt's House.

This meeting covers the whole area of regenerative medicine from ethics of best practice for human embryonic stem cell derivation, through to stem cell commercial translation and regulation. This meeting is our final meeting of the 2006-2007 session of network events and will appropriately finish with a Keynote from the 'Godfather' of regenerative medicine, Dr. Paul Kemp with his predictions for the future. Since this meeting also coincides with the 2nd Birthday of the LRMN, there will be a sparkling wine buffet afterwards!

This meeting and reception are FREE OF CHARGE due to the generous sponsorship of PEPROTECH EC LTD.

image002

Everyone welcome!



SPEAKERS:

KEYNOTE - DR. PAUL KEMP

intercytexlogo
Dr. Paul Kemp is the founder and Chief Scientific Officer of Intercytex plc, a recognised global leader in regenerative medicine. Paul has been heavily involved in commercial regenerative medicine for the last 20 years both in the USA and the UK. After post-doctoral research on the biochemistry of collagen cross-links at Manchester University, he joined Organogenesis (MA, USA) in late 1986 where he was instrumental in the commercial development of Apligraf 'tissue-engineered skin' which was to become the FDA’s first approved manufactured human organ and has currently been used in the USA on over 150,000 patients suffering with chronic leg ulcers.

Paul left Organogenesis in 1997 to return to the UK and founded Intercytex in 1999. This company is devoted to the cellular induction of human tissues and organs and has four products in hair and skin regeneration that are all undergoing clinical studies in the UK, USA and Canada. Paul is international recognised as a leading authority in the field having given numerous presentations at major events and published both papers and patents all whilst building a stock market listed company with over 75 employees based in Cambridge, Manchester and Boston (USA).

ABSTRACT

The use of implanted cells, matrices or morphogenic factors to repair and regenerate tissues and organs is beginning to “come of age” after a long period of development. A continuing stream of exciting developments in basic science are combining with large increases in global funding and the emergence of the first profitable cell based companies in the sector. More people are now treated with cultured allogeneic fibroblasts each year than all other allogeneic living transplants combined apart from blood transfusions. Paul will discuss the various scientific and commercial areas that make up regenerative medicine and give his own personal views of where the commercial sector is going to go over the next few years as more and more patient treatments become available. DEFINITELY NOT TO BE MISSED!!!


PROF. SARAH FRANKLIN
header
Professor Sarah Franklin has an MA in Anthropology from NYU (1986), and completed her PhD at the Birmingham Centre for Cultural Studies in 1992. Between 1992 and 2000 she worked in the Departments of Anthropology at the University of Manchester, NYU, Santa Cruz, and in the Department of Sociology at Lancaster University. She was appointed to the first Chair of its kind in the UK, in the Anthropology of Science, at Lancaster University in 2001. In 2004 she moved to the LSE to a Chair created for her in the Department of Sociology and linked to the BIOS Centre for the Study of Biomedicine, Bioscience and Society, of which she is Acting Director. She has written and edited more than a dozen books on the social aspects of IVF, cloning, embryo research, and stem cells, as well as more than 100 articles, chapters and reports on these topics. Her most recent book, published in May 2007, is titled 'Dolly Mixtures: The remaking of genealogy' which uses Dolly the sheep as an opportunity to begin developing a critical language to identify and evaluate the reproductive possibilities post-Dolly.Throughout her career she has worked closely with clinicians and scientists in an attempt to widen sociological engagement with emerging issues in bioscience and biomedicine by developing collaborative partnerships with the professional and communities, policy makers, and patient groups most closely involved in areas such as assisted conception, embryology, hES derivation, and cloning. She is currently involved in the leadership of HESCCO, with Professor Peter Braude (King's College London), in which she plays an active role as a social scientist participating in the process of devising new protocols for embryo donation to stem cell research and addressing the specific challenges raised by this prominent and controversial field of medical-scientific innovation.

ABSTRACT

One response of the UK research community to the public sensitivity and logistical complexity of embryo donation to stem cell research has been the formation of a national network of 'human embryonic stem cell coordinators' (hESCCO). The aim of hESCCO is to contribute to the formation and implementation of national standards for hES cell derivation and banking, in particular the ethical protocols for patient information and informed consent. A publicly-funded initiative launched by the Medical Research Council in 2003, the hESCCO project is thus an innovative practical intervention within the broader attempt to establish greater transparency, consistency, efficiency and standardization of hES derivation in the UK. A major outcome of the hESCCO initiative has been the drafting and implementation of a national consent form. The lessons learned in this context may be relevant to other practitioners and regulators as a model of best practice in hES cell derivation.


DR. ROD WESTROP

AXORDIA
Dr Rod Westrop is the Chief Operational Officer of Axordia Ltd, one of the UK's leading human embryonic stem cell companies. Rod has over twenty years experience in the biotechnology sector with a number of major life science companies such as Bio-Rad Laboratories and Pharmacia Biotech. He has a wide range of commercial and operational experience related to development and launch of new products for use in both bioprocessing and life science research. Dr Westrop set up Lark Technologies (part of the Cogenics division of Clinical Data) in Europe and established the business as a Good Laboratory Practice (GLP) accredited company with numerous contracts for clinical trial work with top ten pharmaceutical companies. He has an extensive experience of regulatory issues through his work in bioprocessing where he was responsible for setting up biotechnology production units across northern Europe and a background in managing, sales, marketing and business development functions with global responsibility in the life science market

ABSTRACT

Human embryonic stem cells offer great promise in the field of regenerative medicine. There has been huge media interest in the ethical use of such cell lines and in the cures that they purport to bring about. Axordia has found that in order to bring such treatments into the clinic there are a number of significant hurdles to overcome. The regulatory environment is only just becoming clear but there are still areas of uncertainty, there are no set of rules that companies can follow to ensure product registration. Some of the basic tools required for regulatory compliance are not available and are under co development with the establishment of the manufacturing process. Using Axordia as an example the presentation will elucidate what is required from companies by the regulators both in the UK and USA.

AGENDA:

18.00 - Registration + networking over tea and coffee

18.30 - Introduction - Chris Mason (UCL) - Co-organiser - LRMN

18.35 - 'Best practice in human embryonic stem cell derivation - Forming and implementing ethical protocols' - Prof. Sarah Franklin - London School of Economics and Political Science.

19.00 - Q+A Session

19.05 - 'Developing regenerative therapeutics in an emerging regulatory environment' - Dr. Rod Westrop - Axordia Ltd.

19.30 - Q+A Session

19.35 - KEYNOTE - 'The development of regenerative medicine as a future medicine' - Dr. Paul Kemp - Intercytex plc.

20.10 - Q+A Session

20.20 - Closing remarks - Chris Mason (UCL) - Co-organiser - LRMN

20.25 - 22.00 - Networking reception - SECOND BIRTHDAY CELEBRATIONS - enjoy a glass of bubbly or two in the Wolfson Centre for Age-Related Diseases, KCL



This meeting and reception are FREE OF CHARGE due to the generous sponsorship of PEPROTECH EC LTD.

image002

Everyone welcome!


The LRMN also continues to enjoy financial underpinning from both GlaxoSmithKline and the Guy's, King's & St Thomas' Annual Fund, plus invaluable support from the Advanced Centre for Biochemical Engineering, UCL and the Wolfson Centre for Age-Related Diseases, KCL.


To reserve a place, please just email the LRMN Network Secretary, Dr. Louise Mason: louise.mason@regenmednetwork.com


*****PLEASE NOTE THAT THERE IS A CHANGE FROM OUR REGULAR LECTURE THEATRE TO: Lecture Theatre 2, New Hunt's House, Guy's Hospital Campus at London Bridge, London SE1*****

Map: pdf LINK

Everyone welcome!

The LRMN Team look forward to seeing everyone on the 7th June for our final meeting of the 2006-2007 session of network meetings.


NETWORK PRINCIPLE SPONSORS


Pasted Graphic


Guy's, King's and St Thomas' Annual Fund



London Regenerative Medicine Network

"Bringing the regenerative medicine, stem cell and tissue engineering community together"



Google
www www.regenmednetwork.com




Counter